Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial

The Lancet Rheumatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles